Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), a biotech company with a market capitalization of $427 million and currently trading at $24.39, recently reported that Dean Schorno, the company's Executive ...

Rigel Resource Acquisition Corp (RRAC) recently announced the postponement of its extraordinary general meeting scheduled for February 13, 2025. The meeting has been rescheduled to February 28, 2025, ...

This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with a ...

Rigel Pharmaceuticals (RIGL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Singapore-based Rigel Capital is set to announce the final close of its first early-stage fund, Rigel Star, at slightly over $40 million soon, pushing the total capital the firm has raised across its ...

Shares of Rigel Pharmaceuticals (RIGL) have gained 24.6% over the past four weeks to close the last trading session at $21.65, but there could still be a solid upside left in the stock if short ...

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety ...

Implementing environmental, social, and governance (ESG) practices has become a non-negotiable prerequisite for any business ...

Rigel will mail the definitive proxy statement/prospectus to shareholders of record as of the close of business on January 10, 2025. Rigel will hold its Extraordinary General Meeting (the ...